Parkinson's disease (PD) is considered the most common disorder of synucleinopathy,
which is characterised by intracellular inclusions of aggregated and misfolded α-synuclein …

Parkinson's disease (PD) management requires the involvement of movement disorders
experts, other medical specialists, and allied health professionals. Traditionally …

Background Parkinson's disease (PD) is a progressive neurodegenerative disease with no
cure and few treatment options. Its incidence is increasing due to aging populations, longer …

Introduction Although clinician-based assessment through standardized clinical rating
scales is currently the gold standard for quantifying motor impairment in Parkinson's disease …

Background: Immunotherapies targeting α-synuclein aim to limit its extracellular spread in
the brain and prevent progression of pathology in Parkinson's disease (PD). PD03A is a …

Parkinson's disease (PD) is characterized by a variety of motor and non-motor symptoms. As
disease progresses, fluctuations in the response to levodopa treatment may develop, along …

Advanced Parkinson's disease is characterized by periods of poor mobility, dyskinesia and
progressive decline in functional independence of the affected person despite the …

Background Higuchi's fractal dimension (FD) captures brain dynamics complexity and may
be a promising method to analyze resting‐state functional magnetic resonance imaging …

Magnetic Resonance–guided Focused Ultrasound (MRgFUS) represents an effective micro-
lesioning approach to target pharmaco-resistant tremor, mostly in patients afflicted by …

Introduction Human prion diseases are heterogeneous, and often rapidly progressive,
transmissible neurodegenerative disorders associated with misfolded prion protein (PrP) …